Seurat Therapeutics, a US-based drug developer that emerged out of University of Chicago (UChicago), raised $750,000 in a seed round today backed by the institution’s Polsky Innovation Fund, according to Chicago Inno.
The round also featured Scott Meadow, professor of entrepreneurship at UChicago’s Booth School of Business, and unnamed employees of Seurat.
Founded in 2016, Seurat Therapeutics is developing a nasal spray to prevent and treat migraines. The funding will enable the spinout to launch human clinical trials.
Seurat was…
